Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/127352
Title: | Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer |
Author: | Fernández Martínez, Aranzazu Pascual, Tomás Perrone, Giuseppe Morales, Serafín Haba, Juan de la González Rivera, Milagros Galván, Patricia Zalfa, Francesca Amato, Michela Gonzalez, Lucía Prats de Puig, Miquel Rojo, Federico Manso, Luis Paré, Laia Alonso, Immaculada Albanell Mestres, Joan Vivancos, Ana González, Antonio Matito, Judit González, Sonia Fernández Ruiz, Pedro Luis Adamo, Barbara Muñoz Mateu, Montserrat Viladot, Margarita Font, Carme Aya, Francisco Vidal Losada, Maria Jesús Caballero, Rosalía Carrasco, Eva Altomare, Vittorio Tonini, Giuseppe Prat Aparicio, Aleix Martín, Miguel |
Keywords: | Càncer de mama Marcadors bioquímics Expressió gènica Breast cancer Biochemical markers Gene expression |
Issue Date: | 28-Mar-2017 |
Publisher: | Impact Journals |
Abstract: | PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%. |
Note: | Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.15748 |
It is part of: | Oncotarget, 2017, vol. 8, num. 13, p. 21930-21937 |
URI: | http://hdl.handle.net/2445/127352 |
Related resource: | https://doi.org/10.18632/oncotarget.15748 |
ISSN: | 1949-2553 |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
675969.pdf | 3.15 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License